UY40644A - Compuestos derivados benzimidazólicos farmacológicamente activos, con alta afinidad a los receptores MT1 y MT2 de la melatonina y baja afinidad a las enzimas del complejo CYP450, especialmente a la CYP1A2. Sus composiciones farmacéuticas aceptables y procedimiento de producción de los mismos. - Google Patents
Compuestos derivados benzimidazólicos farmacológicamente activos, con alta afinidad a los receptores MT1 y MT2 de la melatonina y baja afinidad a las enzimas del complejo CYP450, especialmente a la CYP1A2. Sus composiciones farmacéuticas aceptables y procedimiento de producción de los mismos.Info
- Publication number
- UY40644A UY40644A UY0001040644A UY40644A UY40644A UY 40644 A UY40644 A UY 40644A UY 0001040644 A UY0001040644 A UY 0001040644A UY 40644 A UY40644 A UY 40644A UY 40644 A UY40644 A UY 40644A
- Authority
- UY
- Uruguay
- Prior art keywords
- pharmaceutical compositions
- melatonin
- receptors
- cyp450
- benzimidazole derivatives
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D235/26—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D235/28—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Anesthesiology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| BR102016024814A BR102016024814A2 (pt) | 2016-10-24 | 2016-10-24 | composto, processo de obtenção do composto, composição farmacêutica, uso do composto e método de tratamento de desordens psiquiátricas e/ou distúrbios do sono |
| UY0001037334A UY37334A (es) | 2016-10-24 | 2017-07-19 | Compuesto, procedimiento de obtención del compuesto, composición farmacéutica, uso del compuesto y método de tratamiento de desórdenes psiquiátricos y/o trastornos del sueño |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UY40644A true UY40644A (es) | 2024-02-29 |
Family
ID=62023150
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UY0001040644A UY40644A (es) | 2016-10-24 | 2017-07-19 | Compuestos derivados benzimidazólicos farmacológicamente activos, con alta afinidad a los receptores MT1 y MT2 de la melatonina y baja afinidad a las enzimas del complejo CYP450, especialmente a la CYP1A2. Sus composiciones farmacéuticas aceptables y procedimiento de producción de los mismos. |
| UY0001037334A UY37334A (es) | 2016-10-24 | 2017-07-19 | Compuesto, procedimiento de obtención del compuesto, composición farmacéutica, uso del compuesto y método de tratamiento de desórdenes psiquiátricos y/o trastornos del sueño |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UY0001037334A UY37334A (es) | 2016-10-24 | 2017-07-19 | Compuesto, procedimiento de obtención del compuesto, composición farmacéutica, uso del compuesto y método de tratamiento de desórdenes psiquiátricos y/o trastornos del sueño |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US10781182B2 (enExample) |
| EP (2) | EP3529234B1 (enExample) |
| JP (1) | JP7194683B2 (enExample) |
| KR (1) | KR102594251B1 (enExample) |
| CN (2) | CN115181108A (enExample) |
| AR (1) | AR109467A1 (enExample) |
| AU (1) | AU2017351756B2 (enExample) |
| BR (1) | BR102016024814A2 (enExample) |
| CL (1) | CL2019001105A1 (enExample) |
| CO (1) | CO2019004756A2 (enExample) |
| DK (1) | DK3529234T3 (enExample) |
| EC (1) | ECSP19032963A (enExample) |
| ES (2) | ES2970546T3 (enExample) |
| FI (1) | FI3529234T3 (enExample) |
| MX (1) | MX392990B (enExample) |
| PE (2) | PE20250558A1 (enExample) |
| PT (1) | PT3529234T (enExample) |
| SG (2) | SG11201903113TA (enExample) |
| UY (2) | UY40644A (enExample) |
| WO (1) | WO2018076090A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LT3640251T (lt) | 2016-10-24 | 2022-03-10 | Astrazeneca Ab | 6,7,8,9-tetrahidro-3h-pirazolo[4,3-f]izochinolino dariniai, tinkami vėžio gydymui |
| BR102016024814A2 (pt) * | 2016-10-24 | 2018-05-08 | Aché Laboratórios Farmacêuticos S.A. | composto, processo de obtenção do composto, composição farmacêutica, uso do composto e método de tratamento de desordens psiquiátricas e/ou distúrbios do sono |
| MX2019008438A (es) | 2017-01-30 | 2019-10-30 | Astrazeneca Ab | Moduladores del receptor de estrogeno. |
| AR121842A1 (es) * | 2020-04-15 | 2022-07-13 | Ache Laboratorios Farmaceuticos Sa | Compuesto de benzimidazol para el tratamiento de trastornos metabólicos |
| IL297216A (en) | 2020-04-24 | 2022-12-01 | Astrazeneca Ab | Dosage regimen for the treatment of cancer |
| JP7719796B2 (ja) | 2020-04-24 | 2025-08-06 | アストラゼネカ・アクチエボラーグ | 医薬製剤 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2658818B1 (fr) | 1990-02-27 | 1993-12-31 | Adir Cie | Nouveaux derives a structure naphtalenique, leur procede de preparation et les compositions pharmaceutiques qui les contiennent. |
| US5260051A (en) | 1990-12-17 | 1993-11-09 | Lever Brothers Company, Division Of Conopco, Inc. | Compositions comprising phosphate ester compounds containing a beneficial reagent component |
| FR2674524B1 (fr) | 1991-03-25 | 1993-05-21 | Adir | Nouveaux amides alkyl heterocycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent. |
| FR2680366B1 (fr) | 1991-08-13 | 1995-01-20 | Adir | Nouveaux derives d'arylethylamines, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent. |
| GB9326192D0 (en) | 1993-12-22 | 1994-02-23 | Glaxo Group Ltd | Chemical compounds |
| US6376666B1 (en) * | 1994-06-10 | 2002-04-23 | Nauchno-Issledovatelsky Institut Farmakologii Rossiiskoi Akademii Meditsinskikh Nauk | 2-mercaptobenzimidazole derivatives possessing pharmacological activity |
| US5496826A (en) | 1994-09-02 | 1996-03-05 | Bristol-Myers Squibb Company | Pharmaceutical methods of using heterocyclic derivatives of N-phenylamides |
| FR2738818B1 (fr) | 1995-09-18 | 1997-12-05 | Valentonine | Nouveaux derives d'oxydation d'indolylalkylamines, et leur utilisation a titre de medicament |
| US6034239A (en) | 1996-03-08 | 2000-03-07 | Takeda Chemical Industries, Ltd. | Tricyclic compounds, their production and use |
| JP2884153B2 (ja) * | 1996-03-08 | 1999-04-19 | 武田薬品工業株式会社 | 三環性化合物、その製造法および剤 |
| ZA9711051B (en) | 1996-12-10 | 1999-06-09 | Bristol Myers Squibb Co | Benzodioxole benzofuran dihydrobenzofuran and benzodioxane melatonergic agents |
| CA2334299A1 (en) | 1998-06-05 | 1999-12-09 | Pierre Dextraze | Heterocyclic cis cyclopropane derivatives as melatonergic agents |
| EP1189900B1 (en) | 1999-06-30 | 2004-01-14 | Bristol-Myers Squibb Company | Heterocyclic aminopyrrolidine derivatives as melatonergic agents |
| EP1467986A1 (en) * | 2002-01-17 | 2004-10-20 | Eli Lilly And Company | Aza-cyclic compounds as modulators of acetylcholine receptors |
| JPWO2005080334A1 (ja) * | 2004-02-23 | 2007-08-02 | 大日本住友製薬株式会社 | 新規ヘテロ環化合物 |
| ES2264641B1 (es) * | 2005-06-17 | 2008-03-01 | Quimica Sintetica, S.A. | Procedimiento para la obtencion de derivados de bencimidazol y sus intermedios. |
| WO2008032164A2 (en) * | 2006-09-12 | 2008-03-20 | Pfizer Products Inc. | Benzimidazolone derivatives |
| WO2008051533A2 (en) * | 2006-10-25 | 2008-05-02 | Takeda Pharmaceutical Company Limited | Benzimidazole compounds |
| RU2401831C2 (ru) * | 2008-12-15 | 2010-10-20 | Алла Хем, Ллс | Средство, снижающее влечение к алкоголю, фармацевтическая композиция и способы ее получения, лекарственное средство и способ лечения |
| BR102016024814A2 (pt) * | 2016-10-24 | 2018-05-08 | Aché Laboratórios Farmacêuticos S.A. | composto, processo de obtenção do composto, composição farmacêutica, uso do composto e método de tratamento de desordens psiquiátricas e/ou distúrbios do sono |
-
2016
- 2016-10-24 BR BR102016024814A patent/BR102016024814A2/pt not_active Application Discontinuation
-
2017
- 2017-07-19 UY UY0001040644A patent/UY40644A/es not_active Application Discontinuation
- 2017-07-19 UY UY0001037334A patent/UY37334A/es active IP Right Grant
- 2017-08-30 AR ARP170102402A patent/AR109467A1/es active IP Right Grant
- 2017-10-23 AU AU2017351756A patent/AU2017351756B2/en active Active
- 2017-10-23 CN CN202210815568.3A patent/CN115181108A/zh active Pending
- 2017-10-23 FI FIEP17865155.0T patent/FI3529234T3/fi active
- 2017-10-23 DK DK17865155.0T patent/DK3529234T3/da active
- 2017-10-23 PT PT178651550T patent/PT3529234T/pt unknown
- 2017-10-23 EP EP17865155.0A patent/EP3529234B1/en active Active
- 2017-10-23 US US16/344,721 patent/US10781182B2/en active Active
- 2017-10-23 KR KR1020197011842A patent/KR102594251B1/ko active Active
- 2017-10-23 MX MX2019004782A patent/MX392990B/es unknown
- 2017-10-23 PE PE2023002494A patent/PE20250558A1/es unknown
- 2017-10-23 ES ES17865155T patent/ES2970546T3/es active Active
- 2017-10-23 EP EP20185268.8A patent/EP3741760B1/en active Active
- 2017-10-23 JP JP2019542758A patent/JP7194683B2/ja active Active
- 2017-10-23 SG SG11201903113TA patent/SG11201903113TA/en unknown
- 2017-10-23 SG SG10202009001TA patent/SG10202009001TA/en unknown
- 2017-10-23 ES ES20185268T patent/ES3013994T3/es active Active
- 2017-10-23 WO PCT/BR2017/050320 patent/WO2018076090A1/en not_active Ceased
- 2017-10-23 PE PE2019000861A patent/PE20191046A1/es unknown
- 2017-10-23 CN CN201780079647.XA patent/CN110088092B/zh active Active
-
2019
- 2019-04-23 CL CL2019001105A patent/CL2019001105A1/es unknown
- 2019-05-09 EC ECSENADI201932963A patent/ECSP19032963A/es unknown
- 2019-05-09 CO CONC2019/0004756A patent/CO2019004756A2/es unknown
-
2020
- 2020-05-13 US US15/930,990 patent/US11091445B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UY40644A (es) | Compuestos derivados benzimidazólicos farmacológicamente activos, con alta afinidad a los receptores MT1 y MT2 de la melatonina y baja afinidad a las enzimas del complejo CYP450, especialmente a la CYP1A2. Sus composiciones farmacéuticas aceptables y procedimiento de producción de los mismos. | |
| CR20160191A (es) | Compuestos derivados de piridilo bicíclicos fusionados a anillo como inhibidores de fgfr4 | |
| CO2017011017A2 (es) | Azabenzimidazoles y su uso como moduladores del receptor ampa | |
| MX390348B (es) | Compuestos de benzimidazol como inhibidores de c-kit | |
| MX380753B (es) | Lactamas bicíclicas y métodos de uso de las mismas. | |
| MX2019010541A (es) | Compuestos de imidazo-piperidina fusionada como inhibidores de jak. | |
| CL2012002057A1 (es) | Compuestos macrociclicos sustituidos, como inhibidores del virus de la hepatitis c; proceso de preparacion de dichos compuestos; composicion farmaceutica que los comprende, utiles como agente antivirales. | |
| MX2019001096A (es) | Antagonistas del receptor 7/8 tipo toll (tlr7/8) y uso de los mismos. | |
| CR20170575A (es) | Nuevos derivados bicíclicos, un proceso para su preparación y composiciones farmacéuticas que los continen. | |
| UY33943A (es) | Derivados espirocíclicos de isoxazolina como agentes antiparasitarios. | |
| CU20160063A7 (es) | Derivados de pirazol fusionados activos como moduladores del receptor de farnesoide x | |
| MX420195B (es) | Compuestos macrocíclicos como agonistas de sting y métodos y usos de los mismos | |
| UY34220A (es) | Indazoles, composiciones farmacéuticas y uso de los mismos | |
| MX2015011367A (es) | Ciclodextrina y formulaciones de conjugados anticuerpo-farmaco. | |
| UY34541A (es) | ?derivados de dihidro-benzo-oxazina y dihidro-pirido-oxazina?. | |
| NI202000028A (es) | Nuevos derivados macrocíclicos, su procedimiento de preparación y las composiciones farmacéuticas que los contienen | |
| MX373652B (es) | Imidazopirazinas y pirazolopirimidinas y su uso como moduladores del receptor de ampa. | |
| MX393879B (es) | Métodos de preparación de niraparib. | |
| GT201600269A (es) | Derivados de indano e indolina y el uso de los mismos como activadores de la guanilato ciclasa soluble | |
| GT201600091A (es) | Derivados de purina 2, 6-sustituidos y su uso en el tratamiento de trastornos proliferativos | |
| SV2017005381A (es) | Compuestos de imidazopiridazina | |
| MX376414B (es) | Derivados de fenilo como agonistas del receptor de canabinoides 2. | |
| UY33976A (es) | Derivados de pirazolo-pirimidina. | |
| CL2017002498A1 (es) | Piridopirimidinonas y su uso como modulares del receptor nmda | |
| CO2020010306A2 (es) | Compuestos de sulfonimidoilpurinona 7-sustituida y derivados para el tratamiento y profilaxis de cáncer de hígado. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RDES | Application refused |
Effective date: 20241125 |